Paquet AC - Search Results

1

A case-based reasoning system for genotypic prediction of HIV-1 co-receptor tropism.

Evans MC, Paquet AC, Huang W, Napolitano L, Frantzell A, Toma J, Stawiski EW, Goetz MB, Petropoulos CJ, Whitcomb J, Coakley E, Haddad M. Evans MC, et al. Among authors: paquet ac. J Bioinform Comput Biol. 2013 Aug;11(4):1350006. doi: 10.1142/S0219720013500066. Epub 2013 Apr 7. J Bioinform Comput Biol. 2013. PMID: 23859270 Free article.

2

A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large protease/reverse transcriptase and co-receptor tropism database from 2003 to 2012.

Paquet AC, Solberg OD, Napolitano LA, Volpe JM, Walworth C, Whitcomb JM, Petropoulos CJ, Haddad M. Paquet AC, et al. Antivir Ther. 2014;19(4):435-41. doi: 10.3851/IMP2748. Epub 2014 Feb 12. Antivir Ther. 2014. PMID: 24518099

3

Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method.

Evans MC, Phung P, Paquet AC, Parikh A, Petropoulos CJ, Wrin T, Haddad M. Evans MC, et al. Among authors: paquet ac. BMC Bioinformatics. 2014 Mar 19;15:77. doi: 10.1186/1471-2105-15-77. BMC Bioinformatics. 2014. PMID: 24646213 Free PMC article.

4

Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity.

Paquet AC, Baxter J, Weidler J, Lie Y, Lawrence J, Kim R, Bates M, Coakley E, Chappey C. Paquet AC, et al. PLoS One. 2011 Jan 31;6(1):e14638. doi: 10.1371/journal.pone.0014638. PLoS One. 2011. PMID: 21297946 Free PMC article.

5

Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir.

Young TP, Napolitano LA, Paquet AC, Parkin NT, Fransen S, Trinh R, Haddad M, Hackett J Jr, Cloherty GA. Young TP, et al. Among authors: paquet ac. J Virol Methods. 2013 Nov;193(2):693-6. doi: 10.1016/j.jviromet.2013.07.028. Epub 2013 Jul 25. J Virol Methods. 2013. PMID: 23892128

6

Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.

Larson JS, Goodman LJ, Tan Y, Defazio-Eli L, Paquet AC, Cook JW, Rivera A, Frankson K, Bose J, Chen L, Cheung J, Shi Y, Irwin S, Kiss LD, Huang W, Utter S, Sherwood T, Bates M, Weidler J, Parry G, Winslow J, Petropoulos CJ, Whitcomb JM. Larson JS, et al. Among authors: paquet ac. Patholog Res Int. 2010 Jun 28;2010:814176. doi: 10.4061/2010/814176. Patholog Res Int. 2010. PMID: 21151530 Free PMC article.

7

Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012.

Lathouwers E, Gupta S, Haddad M, Paquet A, de Meyer S, Baugh B. Lathouwers E, et al. AIDS Res Hum Retroviruses. 2015 Jun;31(6):628-35. doi: 10.1089/AID.2014.0020. Epub 2015 Mar 31. AIDS Res Hum Retroviruses. 2015. PMID: 25684627

8

Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.

Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA. Huang W, et al. Am J Clin Pathol. 2010 Aug;134(2):303-11. doi: 10.1309/AJCP3BZY4YAFNTRG. Am J Clin Pathol. 2010. PMID: 20660336

9

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.

Bethell R, Scherer J, Witvrouw M, Paquet A, Coakley E, Hall D. Bethell R, et al. AIDS Res Hum Retroviruses. 2012 Sep;28(9):1019-24. doi: 10.1089/AID.2011.0242. Epub 2012 Mar 23. AIDS Res Hum Retroviruses. 2012. PMID: 22098079

10

Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.

Duchnowska R, Sperinde J, Chenna A, Haddad M, Paquet A, Lie Y, Weidler JM, Huang W, Winslow J, Jankowski T, Czartoryska-Arłukowicz B, Wysocki PJ, Foszczyńska-Kłoda M, Radecka B, Litwiniuk MM, Zok J, Wiśniewski M, Zuziak D, Biernat W, Jassem J. Duchnowska R, et al. Clin Cancer Res. 2014 May 15;20(10):2805-13. doi: 10.1158/1078-0432.CCR-13-2782. Epub 2014 Mar 25. Clin Cancer Res. 2014. PMID: 24668646

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters